PT 103
Alternative Names: PT-103Latest Information Update: 19 Dec 2023
At a glance
- Originator Incendia Therapeutics
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 19 Dec 2023 Discontinued for Cancer in USA (unspecified route)
- 12 Sep 2023 Early research in Cancer in USA (unspecified route) prior to September 2023 (Incendia Therapeutics pipeline, September 2023)